Thus, the c.1100delC may not increase the morbidity of patients with familial or sporadic pancreatic cancers.53, 54, 55 However, in recent studies, founder mutations in CHEK2 (including 1100delC, IVS2+1G > A, del5395, and I157T) were found to increase the risk of familial pancreatic ductal cancer, especially the I157T mutant. Here, CHEK2 is linked to familial pancreatic carcinoma.